Rare diseases
Investigational molecules
Locations
A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)
AustriaA Phase 2a Study of ly4005130 in Adults with Severe Alopecia Areata
The NetherlandsSafety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)
AustriaPhase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer
AustriaStudy of PF-07275315 versus placebo for efficacy and safety in adults with moderate-to-severe chronic obstructive pulmonary disease (COPD)
BulgariaPhase 3 Randomized, Double‑Blind, Placebo‑Controlled Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 2
AustriaSafety Study of NB-4746 with Riluzole and Placebo in Adults with Amyotrophic Lateral Sclerosis (ALS)
ItalyPhase 3 Randomized Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 1
AustriaEvaluation of Anifrolumab Subcutaneous Treatment in Immunosuppressant‑Naïve and Biologic‑Naïve Patients with Systemic Lupus Erythematosus
FranceEfficacy and Safety of LY4005130 Compared with Placebo in Adults with Non‑Segmental Vitiligo
BelgiumLong-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa
BelgiumBI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases
BelgiumTell us about your condition – we search every trial in Europe and connect you with the right site.
